RBC Europe’s Aclaris Therapeutics ACRS Stock Holding History

RBC Europe’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-195	Closed	-$3.51K	–	631
2021 Q3	$3.51K	Hold	195	–	–	﹤0.01%	1076
2021 Q2	$3.42K	Buy	+195	New	+$4.43K	﹤0.01%	1079

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBC Europe's ACRS Position: Q4 2021 in Review

RBC Europe sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 195 shares — an estimated $3.51K sold.

RBC Europe first reported a position in ACRS in Q2 2021 and held it in 2 quarters. The position peaked at $3.51K in Q3 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

RBC Europe reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 195 Aclaris Therapeutics shares in Q4 2021, an estimated $3.51K.
RBC Europe first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 2 quarters.
RBC Europe's Aclaris Therapeutics position peaked at $3.51K in Q3 2021.
133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.